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Background: Recently, incretin hormones, including glucagon-like peptide-1 (GLP-1) analogue and dipeptidyl
peptidase-4 (DPP-4) inhibitor, have been found to regulate glucose metabolism. The aim of this study was to
elucidate the efficacy and safety of the clinical usage of DPP-4 inhibitors in Japan.
Methods: This study was designed as a prospective, open-label, multi-center trial. Patients with diabetes mellitus
type 2 (T2DM) with poor glycemic profiles (HbA1c ≥ 6.2%) in spite of receiving a medical diet, therapeutic exercise,
and/or medications were eligible for this study. The participants received 50 to 100 mg of the DPP-4 inhibitor
sitagliptin once daily for 12 months.
Results: One hundred and eighty-eight subjects were enrolled. After 12 months of sitagliptin treatment, HbA1c
levels decreased (7.65% ± 1.32% to 7.05% ± 1.10%, p < 0.001) as well as fasting plasma glucose (FPG) (145 ±
52 mg/dl to 129 ± 43 mg/dl, p = 0.005). The rate of glycemic control achieved (in accordance with the guidelines
of the Japanese Diabetes Society) significantly increased. Blood pressure and serum levels of triglycerides and
total cholesterol decreased significantly. Furthermore, the Pittsburgh Sleep Quality Index (PSQI) and Diabetes
Symptomatic Scores improved significantly. Adverse events such as hypoglycemia and loss of consciousness
occurred in twenty three subjects (11%).
Conclusions: These results suggest that the actions of DPP-4 inhibitors improve not only glycemic control, but
also blood pressure, lipid profiles, and quality of life (QOL). Sitagliptin is a sound agent for use in the
comprehensive treatment of patients with T2DM.
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In Japan, the Ministry of Health, Labour and Welfare pub-
lished a report on health and nourishment in 2007 [1] that
estimated that 22.1 million people have strongly suspected
diabetes mellitus (DM) (HbA1c (NGSP) ≥ 6.5%) or poten-
tial DM (6.0% ≤HbA1c (NGSP) < 6.5%). This rate has in-
creased 1.3 times compared to that observed in the former
decade, and an upward trend continues to be maintained.
Additionally, the rate of diabetic treatment has increased
compared to that of 10 years ago. However, it has been
reported that 36.5% of affected patients have not received* Correspondence: junoyama@cc.saga-u.ac.jp
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reproduction in any medium, provided the ordiabetic treatment because conventional anti-diabetic
drugs are inconvenient to use and exhibit inadequate effi-
cacy, a short duration of activity, and side effects such as
hypoglycemia, weight gain, and digestive symptoms.
Therefore, these drugs are associated with problems re-
garding safety and tolerability. In 2006, the US Food and
Drug Administration approved the dipeptidyl peptidase-4
(DPP-4) inhibitor sitagliptin. DPP-4 inhibitors are a new
class of anti-diabetic drugs that exhibit different mecha-
nisms of action from conventional anti-diabetic drugs.
Sitagliptin binds to DPP-4 and prevents the breakdown
of glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) [2]. Both GLP-1 and GIP
are types of incretin hormones released by the intestines
that stimulate insulin secretion from β cells [3] andral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Checklist of diabetes symptomatic score
Checklist
1 Are you often thirsty?
2 Do you produce urine frequently?
3 Are you worried about urinary smell?
4 Do you feel numbness of your extremities?
5 Do you have edema in your legs?
6 Do you have cramps in your legs?
7 Are you insensitive to the pain of a small wound or burn?
8 Do you have a feeling of listlessness?
9 Do you feel lightheaded?
10 Is your vision blurry? Is your eyesight getting worse?
Diabetes Symptomatic Score is used to measure the grade of ten diabetic
symptoms. Patients with a high score have worsening of diabetic symptoms.
None: 0 point, Rare: 1 point, Sometimes: 2 points, Frequent: 3 points, Always: 4
points. Maximum: 40 points.
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broken down by DPP-4 [5]. Incretin hormones depend on
the level of blood glucose to stimulate insulin. DPP-4 inhib-
itors are associated with a lower incidence of hypoglycemia
than conventional hypoglycemic drugs.
This study is a single-arm, prospective, multi-center
trial conducted to evaluate the efficacy and safety of the
DPP-4 inhibitor sitagliptin in clinical use. In this trial,
we particularly focused on the effects of sitagliptin on
quality of life (QOL).
Methods
Study design and protocol
The Institutional Review Board of Human Research at
Saga University approved this study and informed consent
was obtained from all participants. Patients with T2DM
(age ≥ 20 years) with poor glycemic control profiles
[HbA1c ≥ 6.2%, as evaluated according to the National
Glycohemoglobin Standardization Program (NGSP)] in
spite of receiving a medical diet, therapeutic exercise, and/
or conventional anti-diabetic medications were recruited.
The exclusion criteria were treatment with insulin, a his-
tory of severe diabetic ketoacidosis or coma, severe
infection, perioperative state, severe trauma, pregnancy,
breast-feeding, renal dysfunction (creatinine clearance <
30 ml/min or serum creatinine: male: ≥ 1.5 mg/dl, female: ≥
1.3 mg/dl), a history of experiencing side effects to
sitagliptin or other unsuitableness. For the participants,
sitagliptin was given as either a new prescription, as an add-
itional prescription to other conventional anti-diabetic
agents, or replaced other anti-diabetic drugs.
The subjects received 50 mg sitagliptin, once a day for
the first 3 months. After 3 months, the dose of sitagliptin
was changed to between (and including) 25 mg/day and
100 mg/day, and other oral hypoglycemic drugs were
added according to the discretion of each physician. The
observation period was 12 months.
Clinical measurements
After 12 months of treatment with sitagliptin, changes in
HbA1c, fasting plasma glucose (FPG), blood pressure,
body weight (BW), body mass index (BMI), total choles-
terol (TC), LDL cholesterol (LDL-C), HDL cholesterol
(HDL-C), triglycerides (TG), 1.5-anhydro-D-glucitol (1.5-
AG), microalbuminuria, and homeostasis model assess-
ment analyses of beta cell function (HOMA-β) and insulin
resistance (HOMA-IR) were assessed. We also assessed
changes in the subjects’ quality of life (QOL) using the
Euro QOL (EQ)-5 Dimensions (EQ-5D), the EQ Visual
Analogue Scale (EQ-VAS), the Pittsburgh Sleep Quality
Index (PSQI), and the Diabetes Symptomatic Score.
The EQ-5D is a generic instrument for measuring
health-related QOL that has been developed and vali-
dated in a number of European countries [6,7]. The EQ-5D describes a patient’s health status according to five
dimensions: mobility, self-care, usual activities, pain/dis-
comfort and anxiety/depression. Each dimension has
three levels that include no problems, some problems or
severe problems. This yields 243 potential combinations
of health states across the five dimensions. Dolan et al. [8]
measured 42 of these health states in a representative sam-
ple of the United Kingdom general population using the
Time Trade-Off method [9]. Based on these evaluations,
the utility scores can be deduced by means of an additive
function. The utility scores may vary between −0.59 (worst
health) and 1.00 (perfect health). In addition to the five di-
mensions, the EuroQol consists of an EQ-VAS ranging
from 0 (worst imaginable health state) to 100 (best im-
aginable health state) [10]. The PSQI is a self-administered
questionnaire used to assess subjective sleep quality dur-
ing the previous month [11]. The self-rated items of the
PSQI generate seven component scores (range of subscale
scores: 0 to 3) for sleep quality, sleep latency, sleep dur-
ation, habitual sleep efficiency, sleep disturbance, use of
sleep medications, and daytime dysfunction. The sum of
these seven component scores yields one global score of
subjective sleep quality (range: 0 to 21), with higher scores
representing poorer subjective sleep quality. The psycho-
metric properties of the PSQI have been confirmed in pre-
vious studies [11,12]. We have used 5.5 points as a cut-off
in the Japanese version of the PSQI global score [6]. The
Diabetes Symptomatic Score is a method for assessing
QOL that was originally developed for the S-DOG trial.
This score is calculated as the sum of the scores, graded 1
to 5, for 10 diabetes-related symptoms (Table 1).
Statistics
Values are expressed as the mean ± SD. To compare
changes in the values of HbA1c, FPG, BW, BMI, BP, lipids,
1.5AG, and HOMA from baseline to after 12 weeks of
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in the values of the EQ-5D, EQ-VAS, PSQI, and Diabetes
Symptomatic Score, we used the Wilcoxon signed-rank
test. Values of p < 0.05 were considered to be statistically
significant.Results
Baseline characteristics
A total of 221 patients agreed to participate in this study.
Of the 221 patients, 14 were excluded due to protocol
violation. Among the 207 enrolled subjects, seven were
excluded due to discontinuing sitagliptin within the first
3 months, and 12 were excluded because data acquisi-
tion to evaluate the efficacy of the drug failed. Therefore,
sitagliptin efficacy over 3 months was evaluated in 188
subjects as efficacy population. The safety of sitagliptin
over 12 months was also evaluated in the 207 enrolled
subjects as safety population (Figure 1).
Table 2 shows the clinical characteristics of the study
subjects prior to the start of treatment with sitagliptin.
The average age of the evaluated subjects was 66.9 years,
91 subjects (48%) were male, the mean duration of dia-
betes was 6.9 years and the mean HbA1c level was
7.65% at baseline.
Effects of sitagliptin on glycemic control
Overall, HbA1c levels decreased in all of the 188 evalu-
ated subjects after 3 months (7.65% ± 1.32% to 7.06% ±
1.07%, p < 0.001) and 12 months (7.05% ± 1.10%, p <
0.001) of sitagliptin treatment (Figure 2a). The HbA1c
decreases per subgroup are described here.
For the 66 subjects who received sitagliptin alone, the
decreases were 7.44% ± 1.31% to 6.72% ± 0.82%, p < 0.001
at 3 months and 6.61% ± 0.82%, p < 0.001 at 12 months.
Eighty-five subjects received sitagliptin along with otherParticipants: n = 221
Subjects evaluated for efficacy
Enrolled subjects: n = 207
3 months
12 months
Evaluation of the safety of sitagliptin
Figure 1 Study Enrollment.anti-diabetic agents, HbA1c level decreases were 7.86% ±
1.25% to 7.22% ± 1.18%, p < 0.001, 3 months and 7.32% ±
1.20%, p < 0.001, 12 months. In subjects with a BMI <
25 kg/m2 (n = 81) and those with a BMI ≥ 25 kg/m2 (n =
80), a decrease in HbA1c levels was observed after 12 -
months of sitagliptin treatment: 7.59% ± 1.16% to 7.06% ±
1.12%, p < 0.001 and 7.68% ± 1.47% to 7.05% ± 1.03%, p <
0.001, respectively (Figure 2b). By age group, HbA1c levels
decreased as follows: in subjects < 65 years of age (n = 65),
8.00% ± 1.59% to 7.29% ± 1.23%, p < 0.001; those 65 to 74 -
years of age (n = 46), 7.61% ± 1.11% to 7.05% ± 0.99%, p <
0.001; and in those ≥ 75 years of age (n = 51), 7.21% ±
0.87% to 6.75% ± 0.96%, p < 0.001 (Figure 2c).
In each subgroup of baseline HbA1c level [<6.9% (n =
56), 6.9% ≤ baseline HbA1c < 8.4% (n = 89), and 8.4% ≤
baseline HbA1c (n = 43)], the HbA1c levels were de-
creased at 3 months (−0.19%, -0.43%, and −1.45%, re-
spectively) (Figure 2d). FPG was also decreased after
3 months (n = 84, 145 ± 52 to 129 ± 43 mg/dl, p < 0.001)
and 12 months of sitagliptin treatment (n = 65, to 129 ±
42 mg/dl, p = 0.005). The rate of glycemic control achieved
(in accordance with the guidelines of the Japanese
Diabetes Society) significantly increased (Figure 2e).
Effects of sitagliptin on blood pressure, lipid profiles and
insulin resistance
BW and BMI decreased after 3 months of sitagliptin treat-
ment (BW: 62.1 ± 14.1 to 61.5 ± 13.8 kg, p = 0.003, BMI:
25.0 ± 4.5 to 24.8 ± 4.5 kg/m2, p = 0.006). At 12 months,
these values had returned to baseline levels (BW: 62.0 ±
13.7 kg, p = 0.800, BMI: 25.1 ± 4.4 kg/m2, p = 0.560)
(Figure 3a, b). Systolic (SBP) and diastolic blood pressure
(DBP) also decreased after 3 months (SBP: 135 ± 18 to
131 ± 17 mmHg, p < 0.001, DBP: 75 ± 12 to 71 ±11 mmHg,
p < 0.001) (Figure 3c, d) as did serum levels of TC and TG
(TC: 201 ± 40 to 191 ± 37 mg/dl, p < 0.001; TG: 161 ± 171n = 188
Excluded for criteria:       
n = 14
Discontinuation of sitagliptin: n = 7
Failed data acquisition: n = 12
Table 2 Baseline characteristics
Enrolled subjects Evaluated subjects
(n = 207) (n = 188)
Age (years) 66.5 ± 12.8 66.9 ± 12.6
Gender Male: 50% (n = 103), Male: 48% (n = 91),
Female: 50% (n = 104) Female: 52% (n = 97)
BMI 25.0 ± 4.4 kg/m2 25.0 ± 4.4 kg/m2
Waist
circumference
89.4 ± 12.8 cm 89.0 ± 12.8 cm
Obesity (BMI > 25) 51% 50%
Duration of DM
(years)
6.8 ± 6.5 6.9 ± 6.6
Smoking status Smoker: 24% Smoker: 23%
Past smoker: 13% Past smoker: 13%
Never: 63% Never: 63%
Alcohol
consumption
Yes: 30% Yes: 29%,
Complications HT: 67%, DL: 55%, HUA:
7%,
HT: 65%, DL: 55%,
Arrhythmia: 5%, CKD
43%
HUA: 6%, Arrhythmia: 5%,
CKD 43%





Combined drugs SU: 49%, BG: 20%, TZD:
28%,
SU: 48%, BG: 22%,
Glinide: 2%, α-GI: 7% TZD: 28%, Glinide: 2%, α-
GI: 7%
BMI, Body mass index; DM, diabetes mellitus; HT, hypertension; DL,
dyslipidemia; HUA, hyperuricemia; CKD, chronic kidney disease; SU,
sulfonylurea; BG, biguanide; TZD, thiazolidinedione; α-GI,
α-glucosidase inhibitor.
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was no change in the levels of 1.5 AG, HOMA-β, and
HOMA-IR observed (Figure 3f, g).
Effects of sitagliptin on QOL
PSQI scores decreased after 12 months of sitagliptin
treatment (4.1 ± 2.9 to 3.4 ± 2.5 points, p = 0.007) in all
subjects (Figure 4a). In the subgroup of subjects with a
PSQI score > 5.5 points, the scores significantly de-
creased both at 3 months (8.0 ± 1.8 to 6.5 ± 3.0 points,
p < 0.001) and 12 months (to 6.2 ± 3.1 points, p < 0.001)
after sitagliptin treatment. The Diabetes Symptomatic
Scores also decreased at both 3 months (5.6 ± 5.71 to
4.4 ± 4.35, p = 0.004) and 12 months (to 3.7 ± 3.65, p =
0.006) (Figure 4b). Among the 10 diabetes symptomatic
questions (Table 2), scores regarding urination (p =
0.013) and paresthesia (p = 0.025) were decreased at 12 -
months. In contrast, the EQ-5D and EQ-VAS scores did
not change significantly (Figure 4c, d).Safety
Twenty-three (11%) of the 207 enrolled subjects suffered
adverse events (AEs) (Table 3). Two subjects (0.96%) ex-
perienced direct sitagliptin-related AEs causing them to
discontinue sitagliptin. One subject suffered from gastro-
intestinal (GI) symptoms, including vomiting, stomach-
aches, and constipation. The other subject experienced
skin eruptions.
Three subjects (1.15%) developed AEs that were sus-
pected to have a causal relationship with sitagliptin.
Hypoglycemia and loss of consciousness occurred in two
subjects (0.96%). Pneumonia/intestinal tuberculosis and
stool abnormality were recognized in one subject.Discussion
Efficacy and safety of sitagliptin
In our study, the HbA1c and FPG levels were reduced at
3 months (HbA1c: 0.59%, FPG: 15.5 mg/dl reduction) and
at 12 months (HbA1c: 0.65%, FPG: 20.2 mg/dl reduction)
after treatment with sitagliptin at a dose of 25 to 100 mg/
day. Our results are similar to those of previous studies
reported in the US [13] and Japan [14]. Nathan et al. [15]
reported that the expected percentage decrease in HbA1c
levels is 1.0% to 2.0% with metformin monotherapy, 1.0%
to 2.0% with sulfonylureas (SUs), 0.5% to 1.0% with
glinides, 0.5% to 0.8% with α-glucosidase inhibitors (α-GI),
0.5% to 1.4% with thiazolidinediones (TZD) and 0.5% to
0.8% with DPP-4 inhibitors. Monotherapy with metformin
or SU exhibits a stronger reduction of HbA1c levels than
a DPP-4 inhibitor alone. However, metformin is associated
with side effects such as GI symptoms and is contraindi-
cated in patients with renal insufficiency. The major side
effects of SUs are hypoglycemia and weight gain. In pa-
tients receiving treatment with SUs, the incidence of
hypoglycemic episodes has been reported to be 17.6% per
year [16]. Side effects appear to be more frequently seen
with metformin or SUs than with sitagliptin. The most
common side effects of TZD are weight gain and fluid re-
tention along with peripheral edema and an increased risk
of congestive heart failure [14,17]. In our study, body
weight and BMI decreased and there was no evidence of
heart failure during sitagliptin treatment. While metfor-
min, glinides, and α-GIs are required to be taken three
times daily, sitagliptin is only taken once daily. Therefore,
sitagliptin should be associated with higher adherence
compared to metformin, glinides, and α-GIs.
In our study, AEs after sitagliptin treatment were seen
in 23 (11%) of the 207 enrolled subjects. In particular,
direct sitagliptin-related AEs such as hypoglycemia and
loss of consciousness were observed in only two sub-
jects (0.96%). A previous pooled analysis [18] reported
that the overall incidence of AEs was similar between
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Figure 2 Serial HbA1c changes in (a) all subjects, (b) BMI-based groups, (c) age-based groups, (d) HbA1c-based groups, and (e) fasting
plasma glucose. HbA1c, hemoglobin A1c; BMI, body mass index. *p < 0.05, **p < 0.01, ***p < 0.001, vs. baseline by paired t-test.
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http://www.cardiab.com/content/12/1/35agents (except for other DPP-4 inhibitors), including
placebos, pioglitazone, metformin, sulfonylureas, sulfo-
nylureas + metformin, and metformin + rosiglitazone
(overall side effects: 63.0% vs. 62.8%, hypoglycemia: 3.4% vs.
10.9%). Therefore, incidence of AEs in this study, including
hypoglycemia, was lower than that reported in the pooled
analysis. This discrepancy appears to be related to differ-
ences in dosage. In our study, subjects received doses be-
tween 50 and 100 mg/day of sitagliptin with only 24
(11.6%) receiving the highest dose of 100 mg. In thepooled analysis, all subjects received 100 mg/day. In previ-
ous studies, sitagliptin did not increase cardiovascular risk
in patients with T2DM [19] and sitagliptin reduced post-
prandial glucose fluctuation and stabilized blood glucose
levels effectively in combination with miglitol through
continuous glucose monitoring (CGM) [20]. On the other
hand, vildagliptin twice a day calmed down the postpran-
dial glucose level as compared to sitagliptin by CGM [21].
The results of this study show that sitagliptin was safe and





































































































































































































































Figure 3 Serial changes of (a) body weight, (b) BMI, (c) blood pressure, (d) lipid profiles including total cholesterol, triglycerides, LDL-
cholesterol and HDL-cholesterol, (e) 1.5 AG, and (f) HOMA-β and –IR. M, months; SBP, systolic blood pressure; DBP, diastolic blood pressure;
LDL, low-density lipoprotein; HDL, high-density lipoprotein; 1.5-AG, 1.5-Anhydro-D-glucitol; HOMA-β, homeostasis model assessment analyses of
beta cell function; HOMA-IR, insulin resistance. *p < 0.05, **p < 0.01, ***p < 0.001, vs. baseline by paired t-test.
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inhibitor.
Effects of DPP-4 inhibitors on blood pressure and lipid
profiles
Systolic and diastolic blood pressure decreased after 3 -
months of treatment with sitagliptin. The active isoforms of
GLP-1 include GLP-1(7–36) amide and glycine-extended
GLP-1(7–37) [22]. GLP-1(7–36) exhibits vascular actions
via GLP-1 receptor signaling [23]. Additionally, GLP-1(9–
36), a metabolite of GLP-1 (7–36), has vasodilator effects
independent of the GLP-1 receptor in a nitrous oxide/cyclic
guanosine monophosphate (cGMP)-dependent manner
[23]. DPP-4 inhibitors increase the levels of GLP-1, possibly
leading to vasodilatation and blood pressure reduction. In
addition, Gutzwiller et al. [24] showed that a pharmaco-
logical dose of GLP-1 increases sodium excretion in theproximal renal tubule in obese and insulin-resistant men.
Therefore, GLP-1-induced increases in urinary sodium ex-
cretion might also contribute to blood pressure reduction
after sitagliptin treatment.
In our study, serum levels of TC and TG also decreased
after 3 months of treatment with sitagliptin. Qin et al. [25]
showed that GLP-1 decreases the intestinal lymph flow
and reduces triglyceride absorption and apo B and apo A-
IV production in rats. Vildagliptin, another DPP-4 inhibi-
tor, has been shown to reduce the hepatic expression of
genes important for cholesterol synthesis, including
phosphomevalonate kinase and mevalonate decarboxylase
in wild-type mice [26]. Prolonged DPP-4 inhibition modu-
lates the expression of genes important for fatty acid oxi-
dation,including acyl-coenzyme dehydrogenase medium
chain and Acyl-CoA synthetase. In addition, DPP-4 inhibi-
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Figure 4 Effects of sitagliptin on QOL. (a) PSQI the Pittsburgh Sleep Quality Index, (b) the Diabetes Symptomatic Score, (c) Euro QOL (EQ)-5
Dimensions (EQ-5D), and (d) the EQ Visual Analogue Scale (EQ-VAS). *p < 0.05, **p < 0.01, **p < 0.001, vs. baseline by Wilcoxon signed-rank test.
Table 3 Adverse events
Event Number
Death (cause unknown) 1
Worsening of vomiting, stomachache, constipation 1
Loss of consciousness 1
Hypoglycemia 1
Intestinal tuberculosis, pneumonia 1
Stool abnormality 2
Acute myocardial infarction 1
Thrombocytopenia 1
Worsening of heart failure 1
New onset of dyslipidemia 3
Bleeding or ulcer of GI tract 2
Liver dysfunction 4
Elevation of CPK 2
Fever and poor physical health 1
Skin disease including eruption 2
Total number of incidents 24 in 23 subjects
GI, gastric intestinal; CPK, creatinine phosphokinase.
Liver dysfunction is defined as elevated (> 2.5 × the upper limit of normal)
alanine aminotransferase or aspartate aminotransferase.
Elevation of CPK is defined as elevated > 2 × the upper limit of normal.
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palmitoyltransferase 1, independent of incretin receptor ac-
tions [26]. Because these modulations depend on and/or
are independent of incretin receptor actions, sitagliptin may
have the ability to decrease the levels of TC and TG.
QOL and diabetes
QOL, whose evaluation is the major goal of our study, is
improved after sitagliptin treatment. The sleep quality and
PSQI scores decreased after 12 months of treatment with
sitagliptin. Particularly, in the subgroup of poor sleepers
with PSQI scores above 5.5 points, the scores were signifi-
cantly reduced not only after 12 months of treatment, but
also after 3 months of treatment. Sleep disorders are com-
mon in patients with diabetes. Sleep debts decrease carbo-
hydrate tolerance and insulin resistance and increase
sympathetic tone, cortisol levels, and nocturnal catechol-
amine levels [27,28]. Improving sleep disorders with
sitagliptin therapy might improve these states, possibly
preventing cardiovascular disease in patients with T2DM.
Our own QOL assessment scores for diabetes, the Dia-
betes Symptomatic Scores, also decreased after sitagliptin
treatment. Particularly, the scores regarding urinary fre-
quency and paresthesia of the extremities significantly de-
creased 12 months after sitagliptin treatment. Urinary
frequency, which often appears in T2DM patients, is
caused by hyperglycemia-induced polyposia and/or
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polyposia are improved by reductions in FPG after
sitagliptin treatment, thereby decreasing the urinary fre-
quency. Paresthesia of the extremities is characterized by
striking atrophy and/or loss of myelinated and unmyelin-
ated fibers [29]. Hyperglycemia leads to the development
of macrovascular and endoneural microvascular disease in
diabetic nerve tissue via several mechanisms, including
the polyol pathway. We suppose that both reductions of
FPG and vasodilatation, a direct action of DPP-4 inhibi-
tors, leads to improved nerve blood flow and nerve fiber
damage in patients with diabetic neuropathy.
The EQ-5D score represents an independent predictor
of mortality and future cardiovascular events in patients
with T2DM [30]. In our study, however, the EQ-5D
scores did not change after treatment with sitagliptin.
Because the EQ scores before sitagliptin treatment were
as high as 0.84 points, which is close to the cut-off point
for a healthy state, they might not change significantly
after sitagliptin treatment.
Limitations/clinical implications
This was a preliminary, single-arm study of a small num-
ber of subjects. A large-scale, randomized study conducted
over a longer period is needed in the future. However, we
found that sitagliptin exerts significant effects, not only on
glycemic control, but also on improving QOL, blood pres-
sure, and lipid profiles in subjects with T2DM. Although
our results showed efficacy of the drug, we could not pre-
cisely evaluate subjects’ adherence to their dosing regi-
mens. As far as we know, there is no reported data on
patient adherence to DPP-4 inhibitor treatment regimes.
However, adherence to a drug taken once a day is sup-
posed to be higher than conventional drugs taken two or
three times a day, which may affect efficacy. In this study,
the subjects whose rates of adherence were less than 75%
were to be reported as “poor adherence”; all evaluated pa-
tients had good adherence to the dosing regimen.
In this study, treatment with sitagliptin achieved ad-
equate reductions in the levels of HbA1c and significant
increases in the rate of accomplishment of glycemic con-
trol. The use of sitagliptin was shown to be safe and im-
proved the PSQI and Diabetes Symptomatic scores.
Conclusions
The clinical use of the DPP-4 inhibitor sitagliptin has
beneficial effects not only for glucose control, but also for
improving blood pressure, lipid profiles, and QOL regard-
ing sleep quality and diabetes symptoms in addition to be-
ing safe with a high rate of adherence to treatment.
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cholesterol; TG: Triglycerides; T2DM: Type 2 diabetes mellitus;
TZD: Thiazolidinediones; SUs: Sulfonylureas.
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